Drug Profile


Alternative Names: 4197X-RA; Monoclonal antibody ricin A

Latest Information Update: 20 Feb 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Houston Biotechnology
  • Class Eye disorder therapies; Immunotoxins
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Cataracts

Most Recent Events

  • 18 May 2004 Suspended - Preclinical for Cataracts in Japan (unspecified route)
  • 31 Jan 2002 The collaboration between Scil Biomedicals and Medarex has ended
  • 31 Oct 2000 IDM has acquired certain economic interests in MDX RA as part of an expansion of its partnership with Medarex
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top